drugset
drugset / Trial / NCT03630627

A Phase I Study of SB26 in Healthy Volunteers

NCT03630627 ↗

Phase 1 Completed 58 enrolled Samsung Bioepis Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a Phase I, randomized double-blind, placebo-controlled (within a dose group), single and multiple rising dose study of the intravenous administration of SB26 in healthy volunteers.

Timeline

Start
2018-08-22
Primary completion
2020-04-16
Completion
2020-04-16

Drugs

EvaluationDrugModalityDoseRoute
Subject SB26 Unknown — Intravenous

Indications

No indication recorded.